Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Quest Diagnostics Inc. (DGX:NYSE), powered by AI.
Quest Diagnostics Inc. is currently trading at $201.04. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Quest Diagnostics Inc. on Alpha Lenz.
Quest Diagnostics Inc.'s P/E ratio is 22.5.
“Quest Diagnostics Inc. trades at a P/E of 22.5 (fair value) with solid ROE of 14.2%.”
Ask for details →Quest Diagnostics Inc. is a leading healthcare company specializing in diagnostic information services, with a significant presence in the global diagnostics and research sector. The company provides laboratory testing services that are crucial for medical decision-making, serving physicians, hospitals, and patients. Quest Diagnostics processes one of the largest databases of de-identified clinical lab results worldwide, enabling it to deliver actionable diagnostic insights that support disease detection, treatment management, and overall healthcare quality. The company operates at scale, reportedly serving one in three adult Americans and partnering with over half of U.S. physicians and hospitals. Its offerings encompass a broad range of tests, including routine blood work, advanced genetic screenings, and specialized clinical testing. Quest Diagnostics plays a vital role in the healthcare ecosystem by empowering individuals and organizations with timely, reliable data that informs clinical practice and public health decisions. The company’s extensive reach, data-driven approach, and commitment to innovation reinforce its status as a foundational asset within the healthcare and diagnostic services market.
“Quest Diagnostics Inc. trades at a P/E of 22.5 (fair value) with solid ROE of 14.2%.”
Ask for details →Quest Diagnostics Inc. (ticker: DGX) is a company listed on NYSE in the Healthcare sector (Diagnostics & Research). It has approximately 55,000 employees. Market cap is $22.3B.
The current price is $201.04 with a P/E ratio of 22.5x and P/B of 3.11x.
ROE is 14.22% and operating margin is 14.10%. Annual revenue is $11.0B.